AT HOME TEST-GALEAS® Bladder — Bladder Cancer
GALEAS® Bladder — Bladder Cancer Screening Test — £549
A specialist private home urine test for the early, non-invasive detection of bladder cancer. GALEAS® Bladder uses advanced Next-Generation Sequencing (NGS) to analyse a single urine sample for cancer-associated DNA mutations across 23 bladder cancer genes — offering far more sensitivity than standard urine tests, especially for early-stage disease.
The package costs £549, including your private GP consultation, the GALEAS® Bladder home urine sample kit, prepaid return packaging, accredited laboratory analysis, and written GP comments on your results. A £25 prepayment is taken at booking and fully deducted from the package price when you proceed.
What does GALEAS® Bladder detect?
The test screens for cancer-associated DNA mutations in genes commonly altered in bladder cancer, including:
AKT1, BRAF, C3orf70, CDKN1A, CDKN2A, CREBBP, CTNNB1, ELF3, ERBB2, ERBB3, ERCC2, FBXW7, FGFR3, HRAS, KDM6A, KRAS, NRAS, PIK3CA, RHOB, RXRA, SF3B1, TERT (promoter), TP53.
By looking at this broad panel, GALEAS® can detect signals of disease before symptoms appear or before changes are visible on cystoscopy — supporting earlier diagnosis and more confident surveillance.
When is it recommended?
A good choice if you:
Have microscopic blood in your urine (haematuria)
Have persistent urinary symptoms that haven't been explained
Are an ex-smoker or smoker wanting proactive screening
Have had occupational exposure to bladder cancer risk factors
Have a personal history of bladder cancer and want non-invasive surveillance between cystoscopies
Have a family history of bladder or urological cancers
Not suitable as a substitute for urgent investigation if you have frank visible blood in the urine for the first time — that needs urgent assessment via your GP or a urology two-week-wait pathway.
How the test works
A simple home urine sample using a prepaid kit, returned to a UKAS-accredited laboratory for analysis. Results are typically available within 2–3 weeks.
Important: a screening, not diagnostic, test
A negative result is reassuring but does not entirely exclude bladder cancer
A positive result does not mean you have bladder cancer — it indicates an increased likelihood needing further investigation
A positive result is typically followed up with cystoscopy and/or imaging
Your GP will explain this fully at consultation.
What happens with your results
Every result is reviewed by a GMC-registered clinician. If your result is positive or abnormal, we will contact you proactively — at no additional charge — to talk you through what it means and arrange urology referral or onward investigation.
Clinical follow-up
A follow-up consultation is available from £50 (phone/video) or £80 (in person). Urgent results are communicated promptly at no additional charge.
Book your test
Contact us to book. Appointments are available at our Northwest Health branch.
Northwest Health is registered with and regulated by the Care Quality Commission
Location: Briganti Physiotherapy 1
Biomarkers checked
Genes tested:
AKT1, ERBB2, NRAS,BRAF, ERBB3 ,PIK3CA C3orf70, ERCC2, RHOB CDKN1A, FBXW7, RXRA CDKN2A, FGFR3, SF3B1 CREBBP, HRAS, TERT (promoter) CTNNB1, KDM6A, TP53 ELF3, KRAS
Further information regarding these genes can be found here
Biomarkers were identified by Prof Rik Bryan and Dr Doug Ward at Birmingham University, UK. • NGS sequencing panel that targets promoter and exonic regions of 23 of the most relevant genes associated with bladder cancer • Identified by a combination of publicly available data and deep exome sequencing • Exome studies were performed on Caucasian populations • 451 somatic mutations present in the panel have been shown to detect 96% of bladder cancers in over 644 clinical samples.
When is GALEAS® Bladder testing used?
Why is testing for bladder cancer important?
Around 600,000 people worldwide are diagnosed annually with bladder cancer, and over 200,000 deaths are linked to the disease, making it the 10th most common cancer type in the western world.1
However, when diagnosed early, over 90% of patients with bladder cancer will survive 5 years, compared to only 36% of those with a late diagnosis.
When is bladder cancer testing used?
Blood in the urine (haematuria) is one of the most common signs of bladder cancer, and patients with this indication are primarily investigated by cystoscopy, which is uncomfortable, invasive, and an expensive procedure.
To overcome these challenges, the Informed Genomics bladder cancer test requires a simple, non-invasive urine sample and delivers results equivalent to that of cystoscopy for all stages of bladder cancer, including both NMIBC and MIBC.
Laboratory processing time
14days
(and 2 days transport via post)
How does it work?
1. Order Nonacus - GALEAS® Bladder
2. Receive the kit
3. Fill in order forms
4. Produce a Urine sample
5. Post sample kit to a Post Box
6. Results via password protected email and discussion of abnormal results with your own and recommended management plan made
7. Abdnormal results will be followed by a GP and a referral to a Urologist by our partner Private GP services at Pallmall Medical
Accreditations
Nonacus/Informed Genomics manufactures and processes Nonacus - GALEAS® Bladder and offers an efficient and effective, quality-driven service which ensures the high performance of our hereditary cancer testing service. This is underpinned by a strong and robust Quality Management System accredited to UKAS ISO 15189:2012
GALEAS® Bladder is distributed in the UK by Biox Medical Ltd
